Skip to main content

Pharming submits a Marketing Authorisation Application to the European Medicines Agency for Leniolisib

Operational updates

Pharming Group N.V. announces that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, in adults and adolescents 12 years or older.

Read more

Filters

  • Cookies: This website uses cookies Check the cookies page for more information Accept Decline